Pertussis Vaccine Market Report 2026

Pertussis Vaccine Market Overview

• Pertussis Vaccine market size has reached to $5.65 billion in 2025 • Expected to grow to $6.82 billion in 2030 at a compound annual growth rate (CAGR) of 4.1% • Growth Driver: Surge In Childbirth Rates Fuels Growth Of Pertussis Vaccine Market • Market Trend: Advancements In Vaccine Innovation And Regulatory Approvals Strengthen Protection Against Infant Pertussis • North America was the largest region in 2025.

What Is Covered Under Pertussis Vaccine Market?

The pertussis vaccine refers to a vaccine that protects against whooping cough (pertussis), which is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It is designed to stimulate the immune system to produce protective antibodies against the pertussis bacterium, thus reducing the risk of infection and its associated symptoms. The main products of the pertussis vaccine are DTaP (diphtheria, tetanus and acellular pertussis) vaccine, TDaP (tetanus, diphtheria and pertussis) vaccine. The DTaP vaccine, also known as the DTP vaccine, is a combination vaccine that helps protect against three serious bacterial infections, diphtheria, tetanus and pertussis (whooping cough). They are available as whole-cell vaccines and acellular vaccines and are applied over children, adults and infants by various end-users such as vaccination centers, hospitals and clinics.

What Is The Pertussis Vaccine Market Growth Forecast?

The pertussis vaccine market size is expected to see steady growth in the next few years. It will grow to $6.82 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising awareness of adult pertussis vaccination, increasing maternal immunization recommendations, advancements in vaccine safety and efficacy, expansion of healthcare access in emerging economies, growth in combination vaccine development. Major trends in the forecast period include rising adoption of acellular pertussis vaccines, increasing focus on booster immunization programs, expansion of combination vaccines including pertussis, growing adult and maternal pertussis vaccination, strengthening government immunization initiatives.

Global Pertussis Vaccine Market Segmentation

1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine 2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine 3) By Application: Children, Adults, Infants 4) By End-User: Vaccination Centers, Hospitals, Clinics Subsegments: 1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP 2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine

What Is The Driver Of The Pertussis Vaccine Market?

Rising childbirth rates are driving the growth of the pertussis vaccine market going forward. Childbirth is the term for the act of giving birth to a child. It is the culmination of pregnancy, during which the fetus develops in the mother's uterus and marks the beginning of a new life outside the womb. The pertussis vaccine is primarily used for children because it helps protect them from whooping cough and other severe and potentially deadly diseases. For instance, in January 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based national public health organization, the United States witnessed a 1% increase in registered births, totaling 3,664,292, compared to 2022. Therefore, the rising childbirth rates are driving the growth of the pertussis vaccine industry.

Key Players In The Global Pertussis Vaccine Market

Major companies operating in the pertussis vaccine market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Sanofi Pasteur SA, CSL Limited, Serum Institute of India, Biological E. Limited, Bharat Biotech International Limited, Panacea Biotec Limited, PT Bio Farma, Walvax Biotechnology Co. Ltd., Beijing Minhai Biotechnology Co. Ltd., Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Chiron Corporation, Sinovac Biotech Ltd., Takeda Pharmaceutical Company, Novartis AG, Johnson & Johnson

Global Pertussis Vaccine Market Trends and Insights

Major companies operating in the pertussis vaccine market are focusing on developing advanced immunization solutions and securing regulatory approvals to enhance maternal and infant protection against whooping cough. These efforts aim to improve vaccine accessibility, expand recommended use in pregnancy, and reduce pertussis-related morbidity among newborns. For instance, in January 2023, Sanofi S.A., a France-based biopharmaceutical company received U.S. FDA approval for the expanded use of its Adacel (Tdap) vaccine during the third trimester of pregnancy, enabling maternal immunization to help protect infants younger than two months who are at highest risk of severe pertussis infection. This approval allows healthcare providers to actively immunize pregnant individuals, ensuring that protective antibodies are passed to the newborn before birth. As a result, infants gain early-life protection against pertussis, bridging the immunity gap until they can receive their own vaccinations.

What Are Latest Mergers And Acquisitions In The Pertussis Vaccine Market?

In June 2025 BioNet-Asia Co. Ltd., a France-based Thai vaccine biotech group, partnered with PT Bio Farma to develop and distribute a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis) across the ASEAN region. These partnerships aim to strengthen regional healthcare by improving access to essential vaccines, enhancing local manufacturing capacity, and bolstering ASEAN’s preparedness against infectious diseases. Perseroan Terbatas Bio Farma (Persero) is an Indonesia-based company that provides vaccines that protect against pertussis (whooping cough).

Regional Insights

North America was the largest region in the pertussis vaccine market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pertussis Vaccine Market?

The pertussis vaccine market consists of sales of adacel, daptacel, infanrix, kinrix, pediarix, pentacel and quadracel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pertussis Vaccine Market Report 2026?

The pertussis vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pertussis vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.